Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 0.70 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.70 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.70 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.70 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.70 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.70 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.70 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.70 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.70 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440205 | 0.83 | GRIN2D (0.76) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19644507 | 0.83 | GRIA1 (0.50) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1115539 | 0.83 | GRIA1 (0.50) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1439986 | 0.83 | ALDH1A1 (0.63) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| 2,3-Dihydroxy-6,7-Dichloroquinoxaline SCHEMBL30561497 | 0.82 | GRIN2D (1.00) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| 2,3-Dihydroxy-6,7-Dichloroquinoxaline SCHEMBL463608 | 0.82 | GRIN2D (1.00) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3669922 | 0.81 | GRIN2D (0.54) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2416635 | 0.78 | GRIA1 (0.45) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13394503 | 0.78 | GRIA1 (0.45) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1192728 | 0.76 | MAPT (0.57) | GRIA1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375235-B2 | Process for preparing substituted benzimidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| US-20050261211-A1 | Process for preparing substituted benzimidazole compounds | GLAXOSMITHKLINE LLC | 2005-11-24 | — | — | US | claimed |
| EP-1584620-A1 | Process for preparing substituted benzimidazole compounds | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | claimed |
| EP-1272473-B1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| JP-2003530385-A | — | — | 2003-10-14 | — | — | JP | claimed |
| US-20030191127-A1 | Process for preparing substituted benzimidazole compounds | GLAXOSMITHKLINE LLC | 2003-10-09 | — | — | US | claimed |
| EP-1272473-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-01-08 | — | — | EP | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2001077083-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-10-18 | — | — | WO | claimed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-5360795-A | Treating cytomegalo virus and herpes simplex viruses | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1994008456-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5248672-A | POLYSUBSTITUTED BENZIMIDAZOLE NUCLEOSIDES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1993-09-28 | — | — | US | disclosed |
| EP-0556334-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007867-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | GRIA1 3564/4885GRIN2D 4538/4885GRIN3B 4045/4885 |
| US-20030191127-A1 | Process for preparing substituted benzimidazole compounds | EIF2AK2, SAMHD1, ZC3HAV1 | GRIA1 4536/4885GRIN2D 4203/4885GRIN3B 3560/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | GRIA1 2928/4885GRIN2D 4720/4885GRIN3B 3031/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | GRIA1 3564/4885GRIN2D 4538/4885GRIN3B 4045/4885 |
| US-20050261211-A1 | Process for preparing substituted benzimidazole compounds | EIF2AK2, SAMHD1, ZC3HAV1 | GRIA1 4536/4885GRIN2D 4203/4885GRIN3B 3560/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | GRIA1 2928/4885GRIN2D 4720/4885GRIN3B 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.